Using avacopan for treating ANCA-associated vasculitis in real-world settings

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to analyze the variation in clinical practice regarding the early use of avacopan in patients with ANCA-associated vasculitis (AAV) across Europe. It will describe patient characteristics, treatment indications, and clinical outcomes associated with avacopan treatment. By focusing on real-world data, the study seeks to identify key issues in the implementation of avacopan, ultimately addressing knowledge gaps and improving patient care. The cohort will consist of AAV patients who have initiated treatment with avacopan, allowing for a comprehensive understanding of its effects and associated treatment strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Established diagnosis of GPA or MPA
* Treatment (initiation) with avacopan
* Informed consent for use of medical data

Exclusion Criteria:

* If there is no AAV disease activity present that can be supported by an objectifiable clinical measure or assessment
* If a subject is below 16 years old

Where it's running

• Leiden University Medical Center
  Leiden, Netherlands Recruiting

Study contacts

• Principal investigator: Y.K. Onno Teng — Leiden University Medical Center
• Study coordinator: Y.K.O. Teng, MD, PhD
• Email: y.k.o.teng@Lumc.nl
• Phone: +31715262148

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BCT301 CAR-iT cell therapy for hard-to-treat autoimmune diseases

  This early‑phase study tests whether off-the-shelf BCT301 CAR-iT cells can be given safely to adults with refractory autoimmune diseases to see if they can be tolerated and what dose works best.

  Recruiting Early Phase 1 Peking University Third Hospital · Beijing · NCT07301164

• Characterization of Autoreactive B Cells in Autoimmune Diseases and Immune Deficiencies

  Researchers are testing to see how autoreactive B cells behave in people with autoimmune diseases or immune deficiencies to better understand how these cells may contribute to disease.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07251179

• Anti-CD19/BCMA universal CAR-T (RD06-05) for autoimmune diseases

  This early-phase test gives a universal CAR-T therapy (RD06-05) that targets CD19 and BCMA to adults with autoimmune diseases such as SLE/lupus nephritis, ANCA-associated vasculitis, and anti-GBM disease.

  Recruiting Early Phase 1 Nanjing Bioheng Biotech Co., Ltd. · Shanghai, Shanghai Municipality · NCT07203404

• Gallium-68 FAPI PET/CT imaging for people with ANCA-associated vasculitis

  This project will test whether Gallium-68 FAPI PET/CT scans can detect lung and kidney involvement in adults with ANCA-associated vasculitis.

  Recruiting Ruijin Hospital · Shanghai · NCT07151521

• Imaging in Inflammatory Heart Diseases linked to autoimmune disorders

  This study tests how well multimodality imaging (CMR, echocardiography, and PET) detects inflammation in people with suspected inflammatory heart or autoimmune rheumatic diseases.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT07077304

• Epithelial Dysmetabolism and Kidney Fibrosis in ANCA Vasculitis

  This study tests whether alterations in tubulo-interstitial metabolism relate to how quickly kidney function deteriorates in people with ANCA-associated vasculitis compared to other nephropathies.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT07010250

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.